Revolutionary Breakthroughs in Peripheral T-Cell Lymphoma Pipeline: Assessing 40+ Key Companies Revolutionizing Treatment Strategies | Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics Inc, and others

DelveInsight's, "Peripheral T-Cell Lymphomas Pipeline Insight 2023" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Peripheral T-Cell Lymphomas pipeline landscape. It covers the Peripheral T-Cell Lymphomas pipeline drug profiles, including Peripheral T-Cell Lymphomas clinical trials and nonclinical stage products. It also covers the Peripheral T-Cell Lymphomas pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Peripheral T-Cell Lymphomas Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Peripheral T-Cell Lymphomas clinical trials studies, Peripheral T-Cell Lymphomas NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Peripheral T-Cell Lymphomas Pipeline Report
• DelveInsight's Peripheral T-Cell Lymphoma Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Peripheral T-Cell Lymphoma treatment.
• The leading Peripheral T-Cell Lymphoma Companies include Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
• Promising Peripheral T-Cell Lymphoma Pipeline Therapies include Golidocitinib, Tenalisib, AZD4573, COPIKTRA, Zarnestra, Tislelizumab, ONUREG, AFM13, Lacutamab/IPH4102, Tolinapant, Nanatinostat, AUTO4, CFT7455, KT-333, ST-001, Zabinostat, MT-101, Geptanolimab, Duvelisib, STI-3031, Nivolumab, Linperlisib, ONO-4685, LB1901, CD4 CAR T cell therapy, Tipifarnib, CD30.CAR-T, Pembrolizumab, Carfilzomib, Copanlisib, SHR 2554, DT 2216, and others.
• The Peripheral T-Cell Lymphoma companies and academics are working to assess challenges and seek opportunities that could influence Peripheral T-Cell Lymphomas (PTCL) R&D. The Peripheral T-Cell Lymphoma pipeline therapies under development are focused on novel approaches to treat/improve Peripheral T-Cell Lymphomas.

To explore more information on the latest breakthroughs in the Peripheral T-Cell Lymphoma Pipeline treatment landscape of the report, click here @ Peripheral T-Cell Lymphoma Pipeline Outlook- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral T-Cell Lymphoma Overview
Peripheral T-Cell Lymphomas (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. Peripheral T-Cell Lymphomas (PTCL) is classified as a subtype of non-Hodgkin's lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. Peripheral T-Cell Lymphomas (PTCL) specifically affects T-cells, and results when T-cells develop and grow abnormally.

Recent Developmental Activities in the Peripheral T-Cell Lymphoma Treatment Landscape
• In November 2022, Affimed N.V. and Artiva Biotherapeutics Inc. announced a new strategic partnership to jointly develop, manufacture, and commercialize a combination therapy comprised of Affimed's Innate Cell Engager (ICE) AFM13 and Artiva's cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101. Affimed submitted a pre-IND meeting request for the AFM13 and AB-101 co-administered combination therapy to the FDA requesting feedback on the clinical trial design in relapsed/refractory (r/r) Hodgkin lymphoma (HL) with an exploratory arm evaluating the combination in r/r CD30-positive peripheral T-cell lymphoma (PTCL) and a potential path to registration. FDA responded to this request and guided to provide feedback by Q1 2023.
• MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T-cell lymphomas. In October 2022, Myeloid Therapeutics, announced that the US Food and Drug Administration granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+ peripheral T cell lymphoma. Once Myeloid establishes the recommended Phase II dose, a Phase II trial will be initiated to support registration in this patient population.
• In September 2022, Yingli Pharma announced that the first patient had been dosed in a phase II trial looking at a drug to treat peripheral T cell lymphomas - a heterogenous group of generally aggressive neoplasms. The patients were being dosed with linperlisib - a potent inhibitor of the delta isoform of PI3 kinase in patients with relapsed or refractory peripheral T/NK cell lymphoma. This single-arm Phase II study will evaluate the safety, efficacy, and pharmacokinetics of orally administered linperlisib under a strategic collaboration with The University of Texas MD Anderson Cancer Center.
• In September 2022, the European Commission granted an orphan drug designation to nanatinostat and valganciclovir (Nana-val) for use as a potential therapeutic option in patients with peripheral T-cell lymphoma (PTCL). Nanatinostat is selective for certain isoforms of class I HDACs, which is a key component of producing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies. The agent is under investigation in combination with valganciclovir.
• In June 2022, Kymera Therapeutics announced that the FDA granted orphan drug designation to KT-333 for the treatment of Peripheral T-cell Lymphoma (PTCL). KT-333 is a first-in-class degrader of the transcriptional regulator STAT3. STAT3 activation has been shown to be a key modulator of disease in PTCL, and there are currently no approved therapies for PTCL that target this pathway.

For further information, refer to the detailed Peripheral T-Cell Lymphoma Unmet Needs, Peripheral T-Cell Lymphoma Market Drivers, and Peripheral T-Cell Lymphoma Market Barriers, click here for Peripheral T-Cell Lymphoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral T-Cell Lymphoma Emerging Drugs Profile
• HBI-8000: HUYA Bioscience International
The novel epigenetic drug, HBI-8000, is a member of the benzamide class of histone deacetylase inhibitors (HDACIs), working by controlling how tightly DNA is wound around histone proteins, which regulate gene expression. This alters the expression of several proteins involved in processes that arrest the growth of cancer cells, increase tumor immunity and change the tumor microenvironment. Evidence suggests that this mechanism increases the efficacy of other cancer agents such as checkpoint inhibitors.

Peripheral T-Cell Lymphoma Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Peripheral T-Cell Lymphomas (PTCL). The companies which have their Peripheral T-Cell Lymphomas (PTCL) drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, HUYA Bioscience International, Shandong New Time Pharmaceutical, Verastem, Genor Biopharma Co., Ltd., Solasia Pharma K.K., CerRx, Inc., Seattle Genetics, Inc. etc.

Request a sample and discover the recent advances in Peripheral T-Cell Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Peripheral T-Cell Lymphoma Treatment Landscape- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Peripheral T-Cell Lymphoma Pipeline Report
• Coverage- Global
• Companies- Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others
• Pipeline Therapies- Golidocitinib, Tenalisib, AZD4573, COPIKTRA, Zarnestra, Tislelizumab, ONUREG, AFM13, Lacutamab/IPH4102, Tolinapant, Nanatinostat, AUTO4, CFT7455, KT-333, ST-001, Zabinostat, MT-101, Geptanolimab, Duvelisib, STI-3031, Nivolumab, Linperlisib, ONO-4685, LB1901, CD4 CAR T cell therapy, Tipifarnib, CD30.CAR-T, Pembrolizumab, Carfilzomib, Copanlisib, SHR 2554, DT 2216, and others.
• Peripheral T-Cell Lymphoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Peripheral T-Cell Lymphoma Market Drivers and Peripheral T-Cell Lymphoma Market Barriers, click here @ Peripheral T-Cell Lymphoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Peripheral T-Cell Lymphomas (PTCL): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral T-Cell Lymphomas (PTCL) - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Peripheral T-Cell Lymphomas (PTCL) Collaboration Deals
9. Mid Stage Products (Phase II)
10. HBI-8000: HUYA Bioscience International
11. F520: Shandong New Time Pharmaceutical Co., LTD
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd.
15. Drug profiles in the detailed report…..
16. Pre-clinical and Discovery Stage Products
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Peripheral T-Cell Lymphomas (PTCL) Key Companies
20. Peripheral T-Cell Lymphomas (PTCL) Key Products
21. Peripheral T-Cell Lymphomas (PTCL)- Unmet Needs
22. Peripheral T-Cell Lymphomas (PTCL)- Market Drivers and Barriers
23. Peripheral T-Cell Lymphomas (PTCL)- Future Perspectives and Conclusion
24. Peripheral T-Cell Lymphomas (PTCL) Analyst Views
25. Peripheral T-Cell Lymphomas (PTCL) Key Companies
26. Appendix

Got Queries? Find out the related information on Peripheral T-Cell Lymphoma Mergers and acquisitions, Peripheral T-Cell Lymphoma Licensing Activities @ Peripheral T-Cell Lymphoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.